Hepatitis B in Ghana: How Common It Is and What You Can Do

/ Disease Prevention and Managment / By

What is Hepatitis B?

Hepatitis B is a viral infection caused by the Hepatitis B virus (HBV) that attacks the liver. It ranges from a short, mild “acute” illness to a lifelong chronic infection that can lead to cirrhosis (scarring) and liver cancer (hepatocellular carcinoma). HBV is spread by contact with infected blood or bodily fluids—commonly through perinatal transmission (from mother to baby at birth), unprotected sex, unsafe injections, or blood transfusions when precautions are not followed.

How common is Hepatitis B in Ghana?

Estimates vary by data source and population studied, but Ghana is considered a country with a high burden of chronic HBV:

  • National and global profiles report chronic HBV prevalence in the vicinity of ~8–9% of the population (hyperendemic), though local studies and systematic reviews find ranges from around 5% up to the low-to-mid teens in certain communities and blood-donor or clinic samples. globalhep.org+1
  • Older national reviews and region-specific studies often give prevalence figures around 10–13% for chronic carriage in some settings; more recent surveys continue to show substantial pockets of higher prevalence across regions. This variability reflects differences in sampling, testing methods, and population groups (e.g., pregnant women, blood donors, children).

Why the numbers vary:

HBV prevalence is influenced by how and where studies are conducted (community vs. hospital), whether they measure HBsAg (surface antigen) or HBV DNA, and whether they include hard-to-reach populations. Nevertheless, the consistent finding is that HBV remains a public health priority in Ghana.

Why Hepatitis B matters in Ghana

High chronic infection burden increases risk of liver disease and liver cancer in the population. Screening and early treatment reduce long-term complications. globalhep.org

Mother-to-child transmission (MTCT) is a major driver of chronic infection because babies infected at birth have up to a 90–95% chance of becoming chronic carriers unless protected. Introducing a birth-dose vaccine plus appropriate maternal care cuts this transmission dramatically. World Health Organization+1

Co-infection with HIV or Hepatitis D (HDV) complicates care and increases liver disease risk; integrated testing and management are important.

The new push: Birth-dose vaccination in Ghana

A crucial public-health milestone: Ghana has announced plans to introduce the Hepatitis B birth-dose vaccine into its national immunization schedule (from October in the reported rollout), meaning newborns will receive the first dose at birth to prevent vertical transmission. This is a major step toward reducing the number of infants who become chronic HBV carriers.#

Why birth dose matters: When given within 24 hours of birth (and followed by the vaccine series), the birth dose plus maternal screening and, when indicated, antiviral prophylaxis for high-viral-load mothers, can reduce mother-to-child HBV transmission from very high rates to very low rates. The WHO has also updated guidance to expand maternal prophylaxis and simplify treatment criteria.

Who is most at risk?

  • Infants born to HBV-positive mothers (highest risk of chronic infection).
  • Household contacts of people with chronic HBV (shared toothbrushes/razors, sexual contact).
  • Healthcare workers and people exposed to blood via injections or traditional scarification/piercing without sterile equipment.
  • People living with HIV (higher coinfection prevalence and complication risk).

Symptoms — what to watch for.

Many people with chronic HBV have no symptoms for years. When symptoms occur they may include:

  • Yellowing of skin or eyes (jaundice)
  • Dark urine, pale stools
  • Fatigue, nausea, loss of appetite
  • Abdominal pain (right upper quadrant)
    If you have any of these, get tested — but remember: absence of symptoms does not equal absence of infection.

How is Hepatitis B diagnosed?

  • Rapid HBsAg tests: Widely used for screening (point-of-care). A positive HBsAg indicates current HBV infection (acute or chronic).
  • HBV DNA (viral load): Measures how much virus is in the blood; used for treatment decisions and monitoring.
  • Liver function tests (ALT/AST), abdominal ultrasound, and fibrosis assessments: To evaluate liver damage.

Testing is available at major hospitals, some clinics, and at public screening campaigns. Integration into antenatal care is critical for identifying infected mothers

Treatment: what’s available and who should get it

Treatments do not cure HBV in most cases, but they suppress the virus and significantly lower liver-damage risk.

  • First-line oral antivirals: Tenofovir disoproxil fumarate (TDF) and entecavir — both recommended and used in Ghana. These drugs are effective, generally well tolerated, and taken long term. PubMed Central
  • Pegylated interferon: Used in selected patients, less commonly due to side effects and cost.
  • Criteria for treatment: Historically complicated, but WHO’s 2024 guidelines simplified treatment eligibility and expanded access for adolescents and adults; pregnant women with high HBV DNA may be offered antiviral prophylaxis to prevent MTCT.

Access issues in Ghana: While effective drugs are on the formulary and used in teaching hospitals and some clinics, affordability, diagnostic capacity (for viral load testing), and retention in care are challenges. Community programs and international partners support screening, vaccination campaigns, and some treatment access initiatives.

Prevention — the most powerful tools

  1. Vaccination
    • Birth dose (within 24 hours): Prevents mother-to-child transmission. Ghana is adding this to its routine immunization. allAfrica.com
    • Complete vaccine series: If you weren’t vaccinated as a child, adults at risk should receive the full series (or appropriate adult schedule).
  2. Safe childbirth and maternal screening — screen pregnant women; give antivirals to eligible high-viral-load mothers; ensure birth-dose vaccine for newborns. World Health Organization
  3. Infection control — use sterile needles, safe transfusion practices, and safe tattooing/skin-piercing.
  4. Safer sex — condoms reduce sexual transmission.
  5. Household precautions — avoid sharing razors or toothbrushes; clean blood spills safely.

Where to get tested and vaccinated in Ghana.

  • Public hospitals and regional/district health facilities usually offer HBsAg testing and childhood vaccination through EPI clinics. Antenatal clinics increasingly screen pregnant women. PubMed Central+1
  • NGOs and campaign days: Many civil-society groups run free screening and vaccination events. Check local health posts, Ghana Health Service notices, or community centers. globalhep.org
  • Private clinics and diagnostic labs in Accra, Kumasi and larger towns provide testing and sometimes viral-load testing (at cost). If you need antiviral therapy, tertiary hospitals and some specialists can initiate and monitor treatment.

Costs and health insurance

NHIS (Ghana’s National Health Insurance Scheme) may cover some tests and services but coverage of full HBV care (viral loads, long-term antivirals, specialist visits) varies. Out-of-pocket costs remain a barrier for many. Support programs and NGOs sometimes subsidize tests or vaccine doses during campaigns. Always ask your clinic about NHIS and any available subsidies.

Living with Hepatitis B — practical advice

  • Follow your clinician’s plan: adhere to antiviral therapy if prescribed and attend monitoring appointments.
  • Vaccinate household contacts: anyone living with an HBV-positive person who is not immune should be vaccinated.
  • Avoid alcohol and hepatotoxic drugs unless cleared by your provider.
  • Maintain a healthy lifestyle: balanced diet, maintain healthy weight, avoid smoking.
  • Mental health: living with chronic infection can be stressful — seek counseling or peer-support groups.

Community action and health systems — what Ghana can, and is, doing

Ghana’s public health community, NGOs, and international partners are working on multiple fronts: expanding birth-dose vaccination, scaling up maternal screening, deploying community screening and vaccination campaigns, and improving access to diagnostics and affordable antivirals. WHO’s updated 2024 guidelines support simplified treatment and broader prophylaxis — a policy environment that helps countries like Ghana move toward elimination goals

Step-by-step: What you should do today (action checklist)

  • If pregnant: ask for HBV screening at your next antenatal visit. If positive, discuss antiviral prophylaxis and ensure your baby receives the birth-dose vaccine. World Health Organization+1
  • If you’ve never been vaccinated or tested: get an HBsAg test and, if negative, get vaccinated.
  • If you test positive: link to a clinician for staging (viral load, liver tests) and to discuss treatment eligibility.
  • Household contacts: encourage testing and vaccination for partners and household members.
  • Protect infants: ensure newborns receive the birth dose and complete vaccine series.

Final notes — empowering communities

Hepatitis B is a preventable and manageable disease. For Ghana, the combination of a birth-dose vaccine rollout, improved antenatal screening, community testing campaigns, and broader access to affordable antivirals creates realistic pathways toward dramatically reducing new chronic infections and saving lives. If you live in Ghana — whether you’re a parent, health worker, or community leader — your best actions are simple and powerful: get tested, vaccinate newborns and unvaccinated household members, and connect those who are positive to care.

Pregnant? Ask your antenatal clinic for HBV screening and confirm plans for your newborn to receive the birth-dose vaccine. World Health Organization+1

Unsure of your status? Find a local clinic or upcoming screening event and get tested — share this with family and friends.